Clinical Trials for IDEAYA Biosciences

Explore 8 clinical trials worldwide

Showing 1-8 of 8 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: IDEAYA Biosciences

Clinical Trials (8)

Neoadjuvant Darovasertib in Primary Uveal Melanoma

PHASE3Recruiting

520 participants

Started: Oct 31, 2025 · Completed: Mar 31, 2031

1 condition1 sponsor75 locations

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

PHASE1/PHASE2Recruiting

90 participants

Started: Oct 14, 2025 · Completed: May 31, 2029

1 condition1 sponsor10 locations

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

PHASE1/PHASE2Recruiting

73 participants

Started: Dec 13, 2024 · Completed: Jun 16, 2028

5 conditions2 sponsors13 locations

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

PHASE2/PHASE3Recruiting

420 participants

Started: Oct 31, 2023 · Completed: Jan 15, 2028

1 condition1 sponsor68 locations

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

PHASE2Recruiting

160 participants

Started: Jul 3, 2023 · Completed: Apr 30, 2030

1 condition1 sponsor24 locations

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

PHASE1Recruiting

216 participants

Started: Apr 5, 2023 · Completed: May 31, 2027

9 conditions2 sponsors27 locations

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

PHASE1Recruiting

180 participants

Started: Apr 14, 2021 · Completed: Mar 30, 2027

1 condition1 sponsor38 locations

Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

PHASE1/PHASE2Recruiting

341 participants

Started: Jun 28, 2019 · Completed: Mar 31, 2027

4 conditions1 sponsor10 locations